How many drugs treat Severe pain?

Drug Landscape tracks 10 marketed treatments for Severe pain (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/severe-pain.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Severe pain — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Severe pain (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Severe pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Olinvyk	OLICERIDINE	Trevena		Mu-type opioid receptor	2020-01-01
Dilaudid-Hp	Hydromorphone Hydrochloride	Fresenius Kabi	Opioid agonist	Mu-opioid receptor	1984-01-01
Dilaudid-Hp	HYDROMORPHONE	Fresenius Kabi	Opioid Agonist	mu-opioid receptor	1984-01-01
Subutex	BUPRENORPHINE	Purdue Pharma Lp	Partial Opioid Agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
Subutex	Buprenorphine Hydrochloride	Indivior	partial opioid agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
Catapres-Tts-1	CLONIDINE	Lavipharm	Central alpha-2 Adrenergic Agonist	Alpha-2A adrenergic receptor	1974-01-01
Advil	ibuprofen	Generic (originally Boots Group)	Nonsteroidal Anti-inflammatory Drug [EPC]	Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2	1969-01-15
Opana Er	OXYMORPHONE	Endo	Opioid Agonist	Mu-type opioid receptor	1959-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Meperidine Hydrochloride Preservative Free	Meperidine Hydrochloride	Pfizer	Opioid Agonist	Mu-type opioid receptor	1942-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Severe pain
Fresenius Kabi · 2 drugs in Severe pain
Pfizer · 2 drugs in Severe pain
Generic (multiple manufacturers) · 1 drug in Severe pain
Generic (originally Boots Group) · 1 drug in Severe pain
Indivior · 1 drug in Severe pain
Institute of Liver and Biliary Sciences, India · 1 drug in Severe pain
Lavipharm · 1 drug in Severe pain
Medical University of Vienna · 1 drug in Severe pain
MetroHealth Medical Center · 1 drug in Severe pain
Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in Severe pain
Purdue Pharma · 1 drug in Severe pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Severe pain:

Cite this brief

Drug Landscape (2026). Severe pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-pain. Accessed 2026-06-10.

Severe pain full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing